Evidence map›Paper›PMID 34403292›Full record

Trial reportHuman vaccines & immunotherapeutics2021

Prospective clinical trial of hepatitis B vaccination for children with hematological malignancies: a study on the safety and immunogenicity efficacy.

Pengfei Deng, Tian Yang, Hua Zhang, Fen Zhou, Caoyi Xue, Yi Fei, Yijin Gao

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. How does geographical diversity shape vaccine efficacy?Clinical and experimental vaccine research · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pengfei DengDepartment of Immunology, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Tian YangDepartment of Immunology, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Hua ZhangDepartment of Hematology and Oncology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Fen ZhouDepartment of Hematology and Oncology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Caoyi XueDepartment of Immunology, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Yi FeiDepartment of Immunology, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
Yijin GaoDepartment of Hematology and Oncology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Children's Medical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children with hematological malignancies are at increased risk of hepatitis B virus infection. This study assessed the immunogenicity and safety profile of HBV vaccination in pediatric hemato-oncological children. A nonrandomized interventional study was conducted from January 2017 to February 2020 in Shanghai, China. Seventy-three pediatric hemato-oncological children with hepatitis B surface antibody (anti-HBs) titers <10 mIU/ml were recruited. The participants received three doses of recombinant HBV vaccine according to the 0-, 1-, and 6- month immunization schedule. Adverse events following immunization and anti-HBs titers (at baseline, 1 month, and 6 months after inoculation) were recorded. Forty-three males and thirty females with median ages of 9.12 and 9.60 years, respectively, were included. The mean anti-HBs titer was 4.88 ± 2.61 mIU/ml, 893.12 ± 274.12 mIU/ml, and 711.45 ± 337.88 mIU/ml at baseline, one month, and six months after inoculation, respectively (

Indexed as

Hematologic NeoplasmsHepatitis BHepatitis B VaccinesChildChinaCOVID-19FemaleHepatitis B AntibodiesHepatitis B Surface AntigensHumansImmunization, SecondaryMaleProspective StudiesSARS-CoV-2VaccinationHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B Vaccineschildrenhematological malignanciesHepatitis B vaccinationimmunogenicitysafety

Identifiers

PMID34403292
PMCPMC8828061
OpenAlexW3190057955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.